stockrow
Saturday 7 November 2026
Export ELAB’s income statement to Excel — free account
PMGC Holdings Inc.
ELAB Healthcare Biotechnology
PMGC Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $590,100.00, down 65.5% from fiscal 2023.
- Revenue
- +147.7%
- EPS
- +98.4%
- Free cash flow
- −45.0%
Quarter to June 2026, against a year earlier
1.63
0.02
−1.21%
Follow ELAB
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
P/E ratio |
0.00 | — | 0.00 | 0.00 |
Altman Z-Score |
(3.65) | — | 7.22 | — |
P/S ratio |
0.79 | — | 0.00 | 27,712,441.26 |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(5.79) | — | 1.64 | (6.15) |
P/Operating CF |
(0.77) | — | 0.00 | (77,906,223.37) |
Beneish M-Score |
— | — | 0.18 | — |
P/B ratio |
0.17 | — | 0.00 | 0.00 |
Price to Tangible BV |
0.34 | — | 0.00 | 0.00 |
EV/Sales |
(2.63) | — | (1.94) | 27,712,440.93 |
EV/EBITDA |
0.67 | — | 28.85 | 0.00 |
EV/Operating CF |
0.76 | — | 0.73 | (14,980,173.75) |
EV/FCF |
0.71 | — | 0.73 | (14,925,497.51) |
Quick Ratio |
1.60 | 2.22 | 2.57 | 1.99 |
Current Ratio |
1.74 | 3.36 | 3.79 | 2.64 |
Net Debt/EBITDA |
0.87 | 0.95 | 2.95 | 0.65 |
Debt/Assets |
0.66% | 5.94% | 0.00% | 0.00% |
Debt/Equity |
0.01 | 0.08 | 0.00 | 0.00 |
Asset Turnover |
0.05 | 0.00 | 0.48 | 0.00 |
Operating CF/Net income |
0.77 | 0.88 | 1.06 | 0.88 |
Capex/Depreciation |
(4.64) | (36.27) | (0.97) | (4.92) |
Interest Coverage |
(26.72) | (4.98) | (58.51) | (688.85) |
| (106.89%) | (119.12%) | (173.52%) | 0.00% | |
| (70.88%) | (88.07%) | (121.48%) | 0.00% | |
ROIC |
(220.80%) | (71.34%) | (142.57%) | 0.00% |
Return on Tangible Assets |
(203.11%) | (146.85%) | (118.70%) | (177.11%) |
Average Days of Receivables |
210.61 | 0.00 | 0.66 | 6.14 |
Research and Development Expense of Revenue |
24.91% | 0.00% | 0.43% | 29.84% |
Selling, General and Administrative Expense of Revenue |
413.42% | 0.00% | 35.27% | 158.24% |
Intangible Assets out of Total Assets |
0.30 | 0.31 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
(3.25%) | 0.00% | 28.48% | 22.43% |
Graham Net Nets |
1.36 | — | 0.00 | 0.00 |
Graham Number |
0.00 | — | 0.00 | 0.00 |
Earnings Yield |
(1,356.08%) | — | (4.22%) | 0.00% |
Free Cash Flow Yield |
(471.64%) | — | 0.00% | 0.00% |
Revenue per Share |
289.95 | 0.00 | 187,421.34 | 0.08 |
Operating CF per Share |
(2,915.63) | (57,940.87) | (498,681.29) | (0.17) |
Capex per Share |
(220.27) | (4,978.88) | (1,225.69) | 0.00 |
Free Cash Flow per Share |
(3,135.91) | (62,919.75) | (499,906.98) | (0.17) |
Cash per Share |
2,935.53 | 42,074.97 | 364,085.05 | 0.12 |
Shareholders Equity per Share |
3,850.92 | 70,323.13 | 418,825.31 | 0.12 |
Interest Debt per Share |
0.00 | 0.01 | 0.00 | 0.00 |
Book value per Share |
3,850.92 | 70,323.13 | 418,825.31 | 0.12 |
Free Cash Flow |
(6.38) | (5.96) | (4.57) | (1.62) |
Working Capital |
2.93 | 4.25 | 3.62 | 0.96 |
Capital Expenditures |
(0.45) | (0.47) | (0.01) | (0.03) |
Net Current Asset Value |
1.84 | 3.72 | 3.56 | 0.79 |
EV/EBIT |
0.66 | — | 2.92 | 0.00 |
Capex to Sales |
0.76 | 0.00 | 0.01 | 0.04 |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
0.11 | 11.82 | 6.82 | 0.12 |
Cash ROIC |
(45.93%) | (53.30%) | (63.85%) | (70.77%) |
Accounts Receivable Turnover |
3.41 | 0.00 | 214.08 | 0.00 |
Accounts Payable Turnover |
0.69 | 0.00 | 3.05 | 0.00 |
Inventory Turnover |
1.37 | — | 1.59 | 0.00 |
Average Days of Payables |
629.01 | 0.00 | 84.62 | 279.99 |
Days of Inventory on Hand |
85.75 | — | 313.03 | 263.28 |
Average Receivables |
0.17 | 0.00 | 0.01 | — |
Average Payables |
0.59 | 0.31 | 0.19 | — |
Average Inventory |
0.30 | — | 0.36 | — |
Average Assets |
10.93 | 7.09 | 3.54 | — |
Average Common Equity |
7.25 | 5.24 | 2.48 | — |
Columns are period end dates · fundamentals updated 26 Oct 2026